Marco gives oncologists and gastroenterologists immediate access to the latest colorectal cancer evidence, including RAS/BRAF status, microsatellite instability (MSI-H) and ESMO/NCCN treatment guidelines for localized and metastatic disease. The agent synthesizes pivotal trial data to support decisions across every line of therapy.
Some answers to questions we often receive
Yes. Marco synthesizes evidence on the impact of tumor sidedness and RAS/BRAF status on anti-EGFR versus bevacizumab selection, integrating data from FIRE-3 and PEAK trials and current ESMO and NCCN first-line recommendations for metastatic CRC.
Yes. Marco integrates BEACON trial evidence and the encorafenib plus cetuximab regimen for BRAF V600E metastatic CRC, along with guideline recommendations on when and how to use this combination in second line and emerging first-line perspectives.
Marco integrates technical and oncologic resectability criteria for hepatic metastases, evidence on perioperative chemotherapy and long-term survival data per ESMO recommendations and updated hepatobiliary surgery consensus guidelines.
Marco includes complete evidence on immunotherapy in MSI-H CRC, from pembrolizumab in first line (KEYNOTE-177) to nivolumab plus ipilimumab (CheckMate 142), with patient selection criteria, survival data and international guideline recommendations for each clinical scenario.
Marco synthesizes high-risk criteria in stage II (T4, perforation, fewer than 12 lymph nodes examined, MSS) and adjuvant chemotherapy indications with FOLFOX or CAPOX based on current MOSAIC and XELODA evidence, with clear distinction between colon and rectal cancer.
Yes. Marco covers post-surgical and post-treatment surveillance per NCCN and ESMO guidelines, including CEA frequency, imaging and colonoscopy schedules, as well as management of local and metastatic recurrences across different clinical scenarios.
Deciding between anti-EGFR and bevacizumab based on RAS/BRAF/MSI requires synthesizing multiple guidelines that no oncologist can manually keep current.